• Rapport Therapeutics launched a proposed $150 million public offering of convertible senior notes due 2032.
• A 30-day underwriters’ option for $22.5 million in additional notes would bring the total to $172.5 million if fully exercised.
• The general unsecured notes mature December 1, 2032; interest will be payable semiannually.
• The interest rate and initial conversion rate will be determined at pricing.
• Proceeds will support RAP-219 clinical trials, other research and development, and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610271632PRIMZONEFULLFEED9854508) on October 27, 2026, and is solely responsible for the information contained therein.